ArticleImmunity & ageing : I & A2025
Qifuyin against CCL11-Induced cognitive impairment by inhibiting microglial senescence via CCR3 signaling.
Article in Immunity & ageing : I & A, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Urocanic Acid Alleviates Cognitive Impairment by Targeting ZCCHC3 and Suppressing the cGAS-STING-Mediated Senescence.Neurochemical research · 2026Article
- HMC3 revealed: how much do these "Microglia" really tell us?Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundThe chemokine CCL11 is negatively correlated with cognitive function and is able to cause dysfunctions of synaptic plasticity. This research investigate whether CCL11 induce microglia senescence to damage synaptic plasticity and the protective role of Qifuyin.
methodThis study involved the intraperitoneal injection of CCL11 in C57BL/6 mice to create an ageing mouse model. Behavioral tests were conducted to evaluate the changes in cognitive function after Qifuyin treatment. LTP and Golgi staining were used to evaluate synaptic structure and function. Cellular senescence was assessed using SA-β-Gal staining, co-localization of p21 or p16 with Iba-1 was identified using multiplex immunofluorescence, and senescence-associated secretory phenotype (SASP) was evaluated via the Luminex. CCR3 knockout/overexpression HMC3 cells were treated with five brain-entering components of Qifuyin to observe protective effects of Qifuyin.
resultsHere we found that Qifuyin improved the ability of object recognition and memory, spatial learning and memory and conditional fear memory in CCL11-induced cognitive dysfunction of C57BL/6 mice. Qifuyin can improve synaptic plasticity, increase the expression of GAP-43, PSD-95 and SYN in the hippocampus of CCL11-induced mice. Cellular senescence of microglia and the amounts of SASP in the hippocampus were also reduced after Qifuyin treatment. Through the study of HMC3 cells with CCR3 gene knockout/overexpression, it was found that the brain components of Qifuyin could unlock the cell cycle arrest induced by CCL11/CCR3 pathway, reduce the proportion of G0 and G1 cells, reduce the expressions of p16, p21 and SASP, and enhance the synaptic connection of HT-22 cells damaged by HMC3 cells.
conclusionThis study discovered that CCL11 precipitates microglia senescence in brain, resulting in synaptic structural damage and impaired neuronal functional plasticity, hence causing disruptions in learning and memory functions. Qifuyin can mitigate microglial senescence, safeguard synaptic plasticity, and enhance cognitive function.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.